PreCardia

History

2021: Abiomed bought PreCardia

In early June 2021, an artificial developer hearts Abiomed bought the company PreCardia and its catheter system for the treatment of acute decompensated. heart failure Financial the terms of the transaction are not disclosed.

Representatives of Abiomed claim that the deal will complement the company's product portfolio and expand treatment opportunities for patients with acute decompensated heart failure. It is known that regulators in June 2020 called the catheter system PreCardia an advanced device that can change the method of treatment of this group of patients.

Abiomed acquired PreCardia

The PreCardia system is designed to rapidly reduce stagnant events in the venous system and improve general cardiorenal function. The technology includes a balloon catheter and pump controller to address symptoms of acute decompensated heart failure through periodic occlusion of the upper vena cava. Such occlusion prevents congestion and volume overload of the heart in situations where too much water lingers in the body and the heart does not cope with an increased load. In addition, the device allows balancing the increase in sodium levels caused by heart failure.

We look forward to registering and putting PreCardia technology on the market, and also look forward to expanding our relationships with heart failure specialists to improve treatment outcomes for patients with early-stage acute manifestations, said Abiomed CEO Michael R. Minogue in a news release.

Minogue added that the deal "is consistent with the principles of Abiomed - a leader in technological innovation who considers patient wellbeing a priority."^[1]

Notes